EA201370003A1 - METHOD FOR PREDICTING THERAPEUTIC RESPONSE IN PATIENTS WITH MULTIPLE SCLEROSIS - Google Patents

METHOD FOR PREDICTING THERAPEUTIC RESPONSE IN PATIENTS WITH MULTIPLE SCLEROSIS

Info

Publication number
EA201370003A1
EA201370003A1 EA201370003A EA201370003A EA201370003A1 EA 201370003 A1 EA201370003 A1 EA 201370003A1 EA 201370003 A EA201370003 A EA 201370003A EA 201370003 A EA201370003 A EA 201370003A EA 201370003 A1 EA201370003 A1 EA 201370003A1
Authority
EA
Eurasian Patent Office
Prior art keywords
multiple sclerosis
patients
therapeutic response
interferon
patient
Prior art date
Application number
EA201370003A
Other languages
Russian (ru)
Inventor
Ричард А. Рудик
Ричард М. Рансохофф
Original Assignee
Зе Кливленд Клиник Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45348885&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201370003(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Зе Кливленд Клиник Фаундейшн filed Critical Зе Кливленд Клиник Фаундейшн
Publication of EA201370003A1 publication Critical patent/EA201370003A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предусматривается способ для определения эффективности терапии интерфероном-бета (IFN-β) у пациента с рассеянным склерозом. Один этап способа может включать взятие биологического образца у пациента. После взятия биологического образца может быть определен уровень экспрессии по меньшей мере одного интерферон-регулируемого гена и/или его варианта. Повышенная или пониженная экспрессия по меньшей мере одного интерферон-регулируемого гена и/или его варианта по сравнению с контрольным вариантом может указывать на то, что у пациента будет достигнут слабый ответ на IFN-β-терапию.A method is provided for determining the effectiveness of interferon-beta (IFN-β) therapy in a patient with multiple sclerosis. One step of the method may include taking a biological sample from a patient. After taking a biological sample, the expression level of at least one interferon-regulated gene and / or its variant can be determined. Increased or decreased expression of at least one interferon-regulated gene and / or its variant in comparison with the control variant may indicate that the patient will achieve a weak response to IFN-β therapy.

EA201370003A 2010-06-18 2011-06-17 METHOD FOR PREDICTING THERAPEUTIC RESPONSE IN PATIENTS WITH MULTIPLE SCLEROSIS EA201370003A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35626510P 2010-06-18 2010-06-18
PCT/US2011/040810 WO2011159970A2 (en) 2010-06-18 2011-06-17 Method for predicting a therapy response in subjects with multiple sclerosis

Publications (1)

Publication Number Publication Date
EA201370003A1 true EA201370003A1 (en) 2013-06-28

Family

ID=45348885

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201370003A EA201370003A1 (en) 2010-06-18 2011-06-17 METHOD FOR PREDICTING THERAPEUTIC RESPONSE IN PATIENTS WITH MULTIPLE SCLEROSIS

Country Status (22)

Country Link
US (1) US20130089519A1 (en)
EP (1) EP2585100A4 (en)
JP (1) JP2013534419A (en)
KR (1) KR20130036046A (en)
CN (1) CN103140235A (en)
AU (1) AU2011268223B2 (en)
BR (1) BR112012032344A2 (en)
CA (1) CA2802999A1 (en)
CL (1) CL2012003571A1 (en)
CO (1) CO6670574A2 (en)
CR (1) CR20130018A (en)
DO (1) DOP2012000316A (en)
EA (1) EA201370003A1 (en)
EC (1) ECSP13012390A (en)
MA (1) MA34381B1 (en)
MX (1) MX2012015028A (en)
NI (1) NI201200188A (en)
PE (1) PE20130645A1 (en)
SG (1) SG186393A1 (en)
TN (1) TN2012000607A1 (en)
WO (1) WO2011159970A2 (en)
ZA (1) ZA201300019B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015063769A1 (en) * 2013-11-01 2015-05-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Diagnostic methods and kits for determining a personalized treatment regimen for a subject suffering from a pathologic disorder
EP3362168A1 (en) * 2015-10-14 2018-08-22 Novozymes A/S Cleaning of water filtration membranes
CN108304912B (en) * 2017-12-29 2020-12-29 北京理工大学 System and method for realizing pulse neural network supervised learning by using inhibition signal

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60209832T2 (en) * 2002-05-29 2007-01-25 Charité - Universitätsmedizin Berlin A method of identifying Ifn-beta responsive multiple sclerosis patients by determining the expression of Trail
WO2005108610A2 (en) * 2004-04-05 2005-11-17 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for the selection of subjects for multiple sclerosis therapy
US20100209914A1 (en) * 2007-05-25 2010-08-19 Ore Pharmaceuticals , Inc. Methods, systems, and kits for evaluating multiple sclerosis
EP2009440A1 (en) * 2007-06-01 2008-12-31 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Means and methods for classifying samples of multiple sclerosis patients.
EP2334815A4 (en) * 2008-09-16 2012-06-20 Bayer Healthcare Llc Interferon response in clinical samples (iris)

Also Published As

Publication number Publication date
AU2011268223B2 (en) 2014-05-29
CO6670574A2 (en) 2013-05-15
CN103140235A (en) 2013-06-05
SG186393A1 (en) 2013-01-30
JP2013534419A (en) 2013-09-05
BR112012032344A2 (en) 2017-05-30
WO2011159970A2 (en) 2011-12-22
ECSP13012390A (en) 2013-04-30
ZA201300019B (en) 2014-03-26
CA2802999A1 (en) 2011-12-22
WO2011159970A3 (en) 2012-04-19
EP2585100A2 (en) 2013-05-01
EP2585100A4 (en) 2013-11-06
CL2012003571A1 (en) 2013-08-23
KR20130036046A (en) 2013-04-09
MX2012015028A (en) 2013-06-13
NI201200188A (en) 2013-04-15
US20130089519A1 (en) 2013-04-11
MA34381B1 (en) 2013-07-03
CR20130018A (en) 2013-04-26
PE20130645A1 (en) 2013-07-03
TN2012000607A1 (en) 2014-04-01
AU2011268223A1 (en) 2013-01-31
DOP2012000316A (en) 2013-07-31

Similar Documents

Publication Publication Date Title
EA201201657A1 (en) TREATMENT OF DIABETES
UY32177A (en) TREATMENT OF DIABETES IN PATIENTS WITH INSUFFICIENT GLUCEMIC CONTROL TO WEIGHT THERAPY WITH DRUG, ORAL OR NOT, ANTIDIABÉTICO
DK2903616T3 (en) USE OF MASITINIB IN COMBINATION WITH GEMCITABIN TO TREAT A SUBJECT OF PATIENTS WHO HAVE PANCREASANCES
EA201170149A1 (en) NEW ANALOGUES INSULIN OF PROLONGED ACTIVITY
NZ609493A (en) Diagnosis and treatments relating to th2 inhibition
EA200971053A1 (en) METHODS OF TREATMENT OF THE LEAD ULCERS
MX2013003929A (en) Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate.
WO2011156468A8 (en) A method of predicting clinical outcomes for melanoma patients using circulating melanoma cells in blood
WO2016201450A3 (en) Cancer treatment and diagnosis
NZ701715A (en) Means and methods for treating dlbcl
MA32274B1 (en) Antiviral therapy
MX2010006090A (en) Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma.
NZ754427A (en) Regulation of glucose metabolism using anti-cgrp antibodies
EA201370003A1 (en) METHOD FOR PREDICTING THERAPEUTIC RESPONSE IN PATIENTS WITH MULTIPLE SCLEROSIS
EP2589665A4 (en) Method for predicting therapeutic effect of immunotherapy on cancer patient, and gene set and kit to be used in the method
DK1778834T5 (en) Methods for the use of regenerative cells in the treatment of renal diseases and disorders
EA201300410A1 (en) STRATIFICATION OF PATIENTS SUFFERING CANCER ON SENSITIVITY TO THERAPY USING PTK2 INHIBITORS
Glauche Therapy of chronic myeloid leukaemia: simulation studies of different treatment combinations and patient-specific risk estimation
Li Understand and Therapeutically Modulate the Stability of Regulatory T Cells
Han et al. Effects of a Natural Contact Program on Decreasing Self-Stigma among Individuals with Schizophrenia in Taiwan
RU2011119308A (en) METHOD FOR PREDICTING THE EFFECTIVENESS OF TREATMENT OF PATIENTS WITH Rhinopharynx Cancer
UA99717U (en) METHOD OF FORECASTING ACHIEVEMENT OF TARGET PRESSURE IN PATIENTS WITH ARTERIAL HYPERTENSION AND DIABETES
RU2007100753A (en) METHOD FOR FORECASTING STABLE REMISSION IN ANTI-VIRAL THERAPY IN PATIENTS WITH ACUTE HEPATITIS WITH
Naveed et al. A66 AIRWAY REMODELING: WHAT'S GOING ON?: A Study Of Mechanism Of Airway Remodeling In Asthma: Mast Cell Proteases Stimulate Matrix Metalloproteinase (mmp-1) Activation And Human Airway Smooth Muscle Growth
Oh et al. Commentary: effect of pregabalin on acid-induced oesophageal hypersensitivity.